ArticleJournal of diabetes investigation2025
Association of lean metabolic dysfunction-associated steatotic liver disease with carotid plaque progression in patients with type 2 diabetes mellitus.
Article in Journal of diabetes investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- MASLD and Atherosclerosis in Patients with Type 2 Diabetes Mellitus: A Systematic Review.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Metabolic dysfunction-associated steatotic liver disease and cardiovascular disease: Emerging insights into the liver-heart axis.Journal of diabetes investigation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionWe aimed to investigate whether lean metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus. MATERIALS AND
methodsWe investigated 828 patients with type 2 diabetes mellitus who underwent baseline abdominal and carotid artery ultrasonography, followed by repeat carotid ultrasonography after 6-8 years. MASLD was confirmed by abdominal ultrasonography, and lean body mass was defined as a body mass index <23 kg/m
resultsAmong the 828 patients, 57 (6.9%), 197 (23.8%), 397 (47.9%), and 177 (21.4%) were classified as lean MASLD, lean without MASLD, non-lean MASLD, and non-lean without MASLD, respectively. After 6-8 years, both lean MASLD (adjusted odds ratio [aOR], 2.57; P = 0.005) and non-lean MASLD (aOR, 1.59; P = 0.029) had a higher risk of atherosclerosis progression than controls (lean without MASLD). No significant difference was observed in the risk of atherosclerosis progression between the lean and non-lean MASLD groups. DISCUSSION: In patients with type 2 diabetes mellitus, both lean and non-lean MASLD were significantly associated with an increased risk of carotid atherosclerosis progression compared to those who were lean without MASLD. This suggests that evaluation of liver steatosis in patients with type 2 diabetes mellitus, regardless of body weight, may help identify individuals at high risk for carotid atherosclerosis progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.